Emerging protein kinase inhibitors for non-small cell lung cancer
作者： Stephen V Liu , Deepa Subramaniam , George C Cyriac , Feras J Abdul-Khalek , Giuseppe Giaccone
DOI: 10.1517/14728214.2014.873403
关键词: Protein kinase A 、 Oncology 、 Dacomitinib 、 Targeted therapy 、 Cancer research 、 KRAS 、 Medicine 、 Anaplastic lymphoma kinase 、 Epidermal growth factor receptor 、 Kinase 、 ROS1 、 Internal medicine 、 Pharmacology (medical) 、 Pharmacology
摘要: Introduction: In the current paradigm of precision medicine in non-small cell lung cancer (NSCLC), therapeutic strategy is determined by molecular characteristics. The best examples this approach are kinase inhibitors that selectively target tumors bearing an epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma (ALK) rearrangement. Emerging protein may enhance our ability to effectively treat these and other genomic subtypes NSCLC. Areas covered: This article reviews next-generation targeting EGFR ALK-positive addition, targeted clinical development for specific NSCLC covered, including ROS1, BRAF, RET, HER2, KRAS (upstream MEK kinase), MET, PIK3CA, FGFR1, DDR2, VEGFR AAK. Expert opinion: EGFR-mutant NSCLC, there several with promising activity, most notably dacomitinib CO-1686 acquired resistance to...
informahealthcare.com参考文章(120)
Martin Reck, Rolf Kaiser, Anders Mellemgaard, Jean Yves Douillard, Sergey Orlov, Maciej Jerzy Krzakowski, Joachim Von Pawel, Maya Gottfried, Igor Bondarenko, Meilin Liao, Jose Barrueco, Birgit Gaschler-Markefski, Silvia Novello, Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after first-line chemotherapy: LUME Lung 1, a randomized, double-blind phase III trial. Journal of Clinical Oncology. ,vol. 31, ,(2013) , 10.1200/JCO.2013.31.18_SUPPL.LBA8011
Bruce E Johnson, Mark G Kris, Lynne D Berry, David J Kwiatkowski, Anthony John Iafrate, Marileila Varella-Garcia, Ignacio Ivan Wistuba, Wilbur A Franklin, Marc Ladanyi, Pei-Fang Su, Lecia V Sequist, Fadlo Raja Khuri, Edward B Garon, William Pao, Charles M Rudin, Joan H Schiller, Eric B Haura, Giuseppe Giaccone, John D Minna, Paul A Bunn, None, A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC). Journal of Clinical Oncology. ,vol. 31, pp. 8019- 8019 ,(2013) , 10.1200/JCO.2013.31.15_SUPPL.8019
R. B. Cohen, P. A. Janne, J. A. Engelman, P. Martínez, Y. Nishida, S. Gendreau, B. Wu, E. Felip, A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. ,vol. 28, pp. 3015- 3015 ,(2010) , 10.1200/JCO.2010.28.15_SUPPL.3015
Jeeyun Lee, Seung Eun Lee, So Young Kang, In-Gu Do, Sujin Lee, Sang Yun Ha, Jeonghee Cho, Won Ki Kang, Jiryeon Jang, Sai-Hong Ignatius Ou, Kyoung-Mee Kim, Identification of ROS1 rearrangement in gastric adenocarcinoma Cancer. ,vol. 119, pp. 1627- 1635 ,(2013) , 10.1002/CNCR.27967
M. G. Kris, B. E. Johnson, D. J. Kwiatkowski, A. J. Iafrate, I. I. Wistuba, S. L. Aronson, J. A. Engelman, Y. Shyr, F. R. Khuri, C. M. Rudin, E. B. Garon, W. Pao, J. H. Schiller, E. B. Haura, K. Shirai, G. Giaccone, L. D. Berry, K. Kugler, J. D. Minna, P. A. Bunn, Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). Journal of Clinical Oncology. ,vol. 29, ,(2011) , 10.1200/JCO.2011.29.15_SUPPL.CRA7506
M. Catherine Pietanza, Thomas James Lynch, Primo N. Lara, John Cho, Ronald H. Yanagihara, Nandagopal Vrindavanam, Naveed Mahfooz Chowhan, Shirish M. Gadgeel, Nathan A. Pennell, Roel Funke, Ben Mitchell, Heather A. Wakelee, Vincent A. Miller, XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. Journal of Thoracic Oncology. ,vol. 7, pp. 219- 226 ,(2012) , 10.1097/JTO.0B013E31822EEBF9
Sai-Hong Ignatius Ou, Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence Critical Reviews in Oncology Hematology. ,vol. 83, pp. 407- 421 ,(2012) , 10.1016/J.CRITREVONC.2011.11.010
Sai-Hong Ignatius Ou, Eunice L. Kwak, Christina Siwak-Tapp, Joni Dy, Kristin Bergethon, Jeffrey W. Clark, D. Ross Camidge, Benjamin J. Solomon, Robert G. Maki, Yung-Jue Bang, Dong-Wan Kim, James Christensen, Weiwei Tan, Keith D. Wilner, Ravi Salgia, A. John Iafrate, Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. Journal of Thoracic Oncology. ,vol. 6, pp. 942- 946 ,(2011) , 10.1097/JTO.0B013E31821528D3
Jin Soo Lee, Vera Hirsh, Keunchil Park, Shukui Qin, Cesar R. Blajman, Reury-Perng Perng, Yuh-Min Chen, Laura Emerson, Peter Langmuir, Christian Manegold, Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR) Journal of Clinical Oncology. ,vol. 30, pp. 1114- 1121 ,(2012) , 10.1200/JCO.2011.36.1709
L. V. Sequist, B. A. Waltman, D. Dias-Santagata, S. Digumarthy, A. B. Turke, P. Fidias, K. Bergethon, A. T. Shaw, S. Gettinger, A. K. Cosper, S. Akhavanfard, R. S. Heist, J. Temel, J. G. Christensen, J. C. Wain, T. J. Lynch, K. Vernovsky, E. J. Mark, M. Lanuti, A. J. Iafrate, M. Mino-Kenudson, J. A. Engelman, Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors Science Translational Medicine. ,vol. 3, ,(2011) , 10.1126/SCITRANSLMED.3002003